Celator Pharmaceuticals, Inc. Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Clinical Oncology Meeting

Published: Jun 06, 2011

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 (cytarabine:daunorubicin) Liposome Injection. Data were presented as a poster discussion at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The results were based on a subgroup analysis, after 12 months of follow-up, in a randomized Phase 2b trial that compared CPX-351 to conventional cytarabine and daunorubicin (7+3 regimen), the current standard of care (ASCO Abstract #6519).

Back to news